ATC Group: G03XC01 Raloxifene

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of G03XC01 in the ATC hierarchy

Level	Code	Title
`1`	G	Genito urinary system and sex hormones
`2`	G03	Sex hormones and modulators of the genital system
`3`	G03X	Other sex hormones and modulators of the genital system
`4`	G03XC	Selective estrogen receptor modulators
`5`	G03XC01	Raloxifene

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Code	Route	Amount	Notes
ORAL	Oral	60 mg

Active ingredients in G03XC01

Active Ingredient
Raloxifene
As a selective oestrogen receptor modulator (SERM), raloxifene has selective agonist or antagonist activities on tissues responsive to oestrogen. It acts as an agonist on bone and partially on cholesterol metabolism (decrease in total and LDL-cholesterol), but not in the hypothalamus or in the uterine or breast tissues.

Related product monographs

Document	Type	Information Source
EVISTA Film-coated tablet	MPI, US: SPL/PLR	FDA, National Drug Code (US)
EVISTA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)
OPTRUMA Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)